EA202091629A1 - Гуманизированные и деиммунизированные антитела - Google Patents

Гуманизированные и деиммунизированные антитела

Info

Publication number
EA202091629A1
EA202091629A1 EA202091629A EA202091629A EA202091629A1 EA 202091629 A1 EA202091629 A1 EA 202091629A1 EA 202091629 A EA202091629 A EA 202091629A EA 202091629 A EA202091629 A EA 202091629A EA 202091629 A1 EA202091629 A1 EA 202091629A1
Authority
EA
Eurasian Patent Office
Prior art keywords
present
antibodies
amyloidosis
amyloid
amyloid peptide
Prior art date
Application number
EA202091629A
Other languages
English (en)
Inventor
Енс-Ульрих Рафельд
Стивен Гиллис
Торе Хеттман
Штефан Шиллинг
Мартин Кляйншмидт
Original Assignee
Виворайон Терапьютикс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Виворайон Терапьютикс Аг filed Critical Виворайон Терапьютикс Аг
Publication of EA202091629A1 publication Critical patent/EA202091629A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к гуманизированным и деиммунизированным антителам, которые связываются с эпитопом на N-конце пироглутаматного варианта бета-амилоидного пептида (A N3pE), и к профилактическому и терапевтическому лечению заболеваний и состояний, которые связаны с накоплением и отложением амилоидных пептидов, таких как амилоидоз, являющийся группой нарушений и аномалий, ассоциированных с пироглутаматным вариантом амилоидного пептида, как, например, болезнь Альцгеймера, синдром Дауна, церебральная амилоидная ангиопатия и другие связанные аспекты. Более конкретно, оно относится к применению моноклональных антител по настоящему изобретению для связывания пироглутаматного варианта бета-амилоидного пептида в плазме крови, головном мозге и спинномозговой жидкости для предупреждения накопления или для регрессии отложения A N3pE в пределах головного мозга и в различных тканях на периферии и для уменьшения выраженности амилоидоза. Настоящее изобретение дополнительно относится к диагностическим анализам для проведения диагностики амилоидоза с применением антител по настоящему изобретению.
EA202091629A 2018-01-31 2019-01-29 Гуманизированные и деиммунизированные антитела EA202091629A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18154427.1A EP3521308B1 (en) 2018-01-31 2018-01-31 Humanized and de-immunized antibodies
PCT/EP2019/052100 WO2019149689A1 (en) 2018-01-31 2019-01-29 Humanized and de-immunized antibodies

Publications (1)

Publication Number Publication Date
EA202091629A1 true EA202091629A1 (ru) 2020-09-23

Family

ID=61132161

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091629A EA202091629A1 (ru) 2018-01-31 2019-01-29 Гуманизированные и деиммунизированные антитела

Country Status (14)

Country Link
US (1) US20210032315A1 (ru)
EP (1) EP3521308B1 (ru)
JP (1) JP7337077B2 (ru)
KR (1) KR20200116095A (ru)
CN (1) CN111670196A (ru)
AU (1) AU2019214280A1 (ru)
BR (1) BR112020015194A2 (ru)
CA (1) CA3088606A1 (ru)
EA (1) EA202091629A1 (ru)
IL (1) IL276101A (ru)
MX (1) MX2020007986A (ru)
SG (1) SG11202006378PA (ru)
WO (1) WO2019149689A1 (ru)
ZA (1) ZA202004784B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113957095A (zh) * 2021-10-22 2022-01-21 江苏集萃药康生物科技股份有限公司 一种用于构建阿尔兹海默症动物模型的构建方法及其核酸组合物和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5981830A (en) 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
ES2468546T3 (es) 2006-11-09 2014-06-16 Probiodrug Ag Nuevos inhibidores de glutaminil ciclasa
EP2086960B1 (en) 2006-11-09 2014-03-05 Probiodrug AG Novel inhibitors of glutaminyl cyclase
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
DK2118101T3 (da) 2007-03-09 2013-01-02 Probiodrug Ag IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5675344B2 (ja) 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのニトロビニルジアミン誘導体
US9512082B2 (en) 2007-04-18 2016-12-06 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8772508B2 (en) 2007-04-18 2014-07-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
ES2474693T3 (es) 2007-04-18 2014-07-09 Probiodrug Ag Derivados de ciano-guanidina como inhibidores de glutaminil ciclasa
WO2008128982A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors
EP2142536B1 (en) 2007-04-20 2015-10-21 Probiodrug AG Aminopyrimidine derivatives as glutaminyl cyclase inhibitors
CN101802000A (zh) 2007-09-12 2010-08-11 前体生物药物股份公司 转基因小鼠
EP2320942B1 (en) 2008-07-21 2018-03-14 Probiodrug AG Diagnostic antibody assay
ES2599621T3 (es) 2008-09-04 2017-02-02 Probiodrug Ag Nuevos inhibidores
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US9512115B2 (en) 2013-03-15 2016-12-06 Probiodrug Ag Inhibitors
CN108699139B (zh) 2015-07-16 2022-06-24 维沃永治疗公众有限公司 人源化抗体
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途

Also Published As

Publication number Publication date
WO2019149689A1 (en) 2019-08-08
EP3521308A1 (en) 2019-08-07
SG11202006378PA (en) 2020-08-28
EP3521308B1 (en) 2024-03-13
IL276101A (en) 2020-08-31
ZA202004784B (en) 2021-09-29
EP3521308C0 (en) 2024-03-13
AU2019214280A1 (en) 2020-07-23
MX2020007986A (es) 2020-09-09
CA3088606A1 (en) 2019-08-08
JP2021512100A (ja) 2021-05-13
JP7337077B2 (ja) 2023-09-01
US20210032315A1 (en) 2021-02-04
CN111670196A (zh) 2020-09-15
BR112020015194A2 (pt) 2020-12-29
KR20200116095A (ko) 2020-10-08

Similar Documents

Publication Publication Date Title
EA201890313A1 (ru) Гуманизированные антитела к пироглутаматному варианту бета-амилоида
AU2018255221B2 (en) Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
WO2007068412A3 (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
MX2009013503A (es) Anticuerpo monoclonal anti-amiloide-beta.
NO20090156L (no) Humanisert antistoff
JP2017113004A5 (ru)
WO2008060364A3 (en) Humani zed antibody against amyloid beta
JP2019529336A (ja) 過リン酸化タウに特異的な抗体およびその使用方法
EP2650308A3 (en) Use of anti-amyloid beta antibody in ocular diseases
JP2014502141A5 (ru)
WO2009048539A3 (en) Use of anti-amyloid beta antibody in ocular diseases
EA201891286A1 (ru) АНТИ-БЕТА-АМИЛОИДНЫЙ ПЕПТИД N3pGlu АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2019098763A3 (ko) 알파-시누클레인에 대한 항체 및 그 용도
RU2017103446A (ru) УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ
US11377487B2 (en) Factor H potentiating antibodies and uses thereof
CA2765602A1 (en) N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders
UA102368C2 (ru) СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ β-АМИЛОИДА 1-42 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ ИМЕЮТ ТЕРАПЕВТИЧЕСКИЕ СВОЙСТВА
MX2022006676A (es) Nuevas moleculas para terapia y diagnostico.
EA202091629A1 (ru) Гуманизированные и деиммунизированные антитела
PH12012501882A1 (en) Humanized antibody against amyloid beta
RU2013130002A (ru) Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками
KR20170058922A (ko) 인자 h 강화 항체 및 그의 용도
RU2011128702A (ru) Средства для лечения пузырчатки, содержащие антитела против лиганда fas
CL2018002690A1 (es) Variantes del anticuerpo humanizado ban2401 que se une específicamente a protofibrillas con una vida media serica aumentada composiciones farmacéuticas y usos en el tratamiento del alzheimer y otras enfermedades neurodegenerativas (divisional de la solicitud n° 53-2017).
EA202090961A1 (ru) Антитела к -синуклеину и их применения